Nutra Pharma has received approval in India for Nyloxin, an over-the-counter pain reliever to treat moderate to severe (stage 2) chronic pain.
Nutra Pharma chairman and CEO Rik J Deitsch said that the Indian approval is the company’s first regulatory authorisation outside the US and represents one of the more significant international market opportunities for Nyloxin.
Following the approval, the firm has accepted orders for the products through their distributor, Nutritional Alliance, for export to India-based importers.
The company’s pain reliever is currently available in the US as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritic pain and pain from repetitive stress.
Nyloxin is also offered in an extra-strength formula for more advanced, Stage 3 chronic pain.
